{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:34:20Z","timestamp":1792704860192,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.clinthera.2014.11.005","type":"journal-article","created":{"date-parts":[[2014,12,6]],"date-time":"2014-12-06T15:26:29Z","timestamp":1417879589000},"page":"1012-1021.e6","source":"Crossref","is-referenced-by-count":45,"title":["Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01275066","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Becky","family":"Schweighardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Jesaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald G.","family":"Musson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Shaywitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.11.005_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.04.002","article-title":"Review of clinical presentation and diagnosis of Mucopolysaccharidosis IVA","volume":"110","author":"Hendriksz","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2014.11.005_bib2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s004390050641","article-title":"Incidence of the mucopolysaccharidoses in Northern Ireland","volume":"101","author":"Nelson","year":"1997","journal-title":"Hum Genet"},{"key":"10.1016\/j.clinthera.2014.11.005_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajmg.a.20314","article-title":"Incidence of the mucopolysaccharidoses in Western Australia","volume":"123A","author":"Nelson","year":"2003","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.clinthera.2014.11.005_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2013.04.009","article-title":"Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder","volume":"109","author":"Yasuda","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2014.11.005_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","article-title":"The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects","volume":"109","author":"Harmatz","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2014.11.005_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-9-32","article-title":"Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey","volume":"9","author":"Hendriksz","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2014.11.005_bib7","doi-asserted-by":"crossref","first-page":"e12194","DOI":"10.1371\/journal.pone.0012194","article-title":"Enzyme replacement in a human model of Mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice","volume":"5","author":"Dvorak-Ewell","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2014.11.005_bib8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.clinthera.2014.11.005_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.clinthera.2014.11.005_bib10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.clinthera.2014.11.005_bib11","doi-asserted-by":"crossref","unstructured":"Hendriksz CJ, Burton BK, Fleming TR. et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A Syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014; May 9 [Epub ahead of print].","DOI":"10.1007\/s10545-014-9715-6"},{"key":"10.1016\/j.clinthera.2014.11.005_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2014.11.005_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10545-013-9587-1","article-title":"Diagnosing mucopolysaccharidosis IVA","volume":"36","author":"Wood","year":"2013","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinthera.2014.11.005_bib14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2014.11.005_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-014-0173-y","article-title":"Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome","author":"Qi","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2014.11.005_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"Benichou","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinthera.2014.11.005_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-8-51","article-title":"Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase","volume":"8","author":"Brands","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2014.11.005_bib18","first-page":"CD009354","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I","volume":"9","author":"Jameson","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814007413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814007413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T05:26:05Z","timestamp":1538025965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814007413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0149291814007413"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.11.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}